Ascend Montclair Pharmacy Launches Medical CBD SalesNote

Aug.22.2022
Ascend Montclair Pharmacy Launches Medical CBD SalesNote
Ascend Montclair pharmacy launched medical CBD last weekend, drawing in a steady crowd of customers.

Last Saturday, Ascend Montclair pharmacy launched medical CBD products during their weekend sale, attracting a steady stream of customers to the pharmacy.

 

Michele DeZao, a 60-year-old from Rockaway, was also among those who came to inspect. Two months ago, she obtained a medical CBD card and this was her second time visiting the pharmacy.

 

The cancer-disabled patient in recovery immediately noticed that the crowd on Saturday was increasing. However, she was relieved to have received priority treatment in the queue reserved only for medical patients to be discharged.

 

The hours between 8am to 10am are reserved exclusively for medical patients, while adult tobacco purchases begin at 10am every day of the week at Ascend Montclair.

 

I have no problem," Dezo said while paying, claiming it helps alleviate stomach pain. "Anyway, people are buying it (adult tobacco), so why not make it legal?

 

On August 20, 2022, Michele DeZao picked up her medical marijuana from Ascend Montclair pharmacy. The pharmacy, located at 395 Bloomfield Avenue, officially opened its doors on Friday at 10am and became the 19th pharmacy in New Jersey to sell adult-use cannabis after weeks of negotiations with the town. Alexandra Pais of NJ Advance Media captured the moment.

 

We appreciate the support of the Montclair community and are excited to share the Ascend experience with people in Montclair and surrounding towns," said Caitlin Fleishman, Public Affairs and Communications Director for Ascend Wellness, the multi-state operator of the pharmacy.

 

Last Tuesday, the Montclair Township administration voted 5-1 in favor of a pre-negotiated settlement agreement with Ascend, allowing for the sale of adult tobacco products.

 

Peter Yacobellis, the town consultant, stated that as part of the settlement agreement, Ascend Montclair will provide "voluntary donations" to various organizations using revenue from adult tobacco sales.

 

In an email, Yacobellis praised Ascend for their incredible generosity towards the citizens of Montclair, particularly their contributions to the Montclair Community Development Corporation and the Montclair Pre-K program. Yacobellis also emphasized the importance of ensuring that low-income and communities of color benefit from the revenue generated by the new cannabis market, as these communities have been disproportionately impacted by legacy marijuana laws.

 

The owner and co-founder of Ascend announced that another New Jersey location in Roselle Park launched adult tobacco sales statewide on April 21 and quickly became one of their top-performing adult cannabis stores in the U.S.

 

Ascend Fort Lee began selling medical marijuana on August 12th and plans to expand into adult CBD in the fall.

 

At Ascend Montclair, "there is a lot of traffic and support," said Fleishman.

 

Statement:

 

This article is compiled from third-party information and is intended solely for industry professionals for discussion and study purposes.

 

This article does not represent the views of 2FIRSTS, nor can 2FIRSTS confirm the truthfulness or accuracy of the article's content. The translation of this article is only intended for industry exchange and research.

 

Due to limitations in translation ability, this article may not accurately reflect the meaning of the original text. Please refer to the original text for accuracy.

 

2FIRSTS is in full agreement with the Chinese government regarding any domestic, Hong Kong, Macau, Taiwan or international issues and positions.

 

The compilation information is the property of the original media and author. If there is any infringement, please contact us for deletion.

 


Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

FDA Tobacco Center Plans Faster Review Process for Certain Supplemental PMTAs
FDA Tobacco Center Plans Faster Review Process for Certain Supplemental PMTAs
FDA Center for Tobacco Products Acting Director Bret Koplow issued a statement on May 7 outlining new steps to accelerate tobacco product premarket application review. The statement said CTP reduced the backlog of applications by approximately 70% in 2025 and that there is no longer a queue for PMTAs pending acceptance review.
May.09 by 2FIRSTS.ai
Philip Morris International Announces IQOS and Devialet Collaboration at Milan Design Week 2026
Philip Morris International Announces IQOS and Devialet Collaboration at Milan Design Week 2026
Philip Morris International announced on April 20 that IQOS has partnered with French acoustic engineering company Devialet to launch “Soundsorial Design” at Milan Design Week 2026. The collaboration includes an immersive exhibition and a limited-edition product set named “Soundsorial.” The exhibition will run from April 20 to April 27 at Opificio 31 in Milan.
Apr.22 by 2FIRSTS.ai
Product | ZYN Adds Tropical Flavor and Expands 1.5mg Nicotine Options in the Philippines
Product | ZYN Adds Tropical Flavor and Expands 1.5mg Nicotine Options in the Philippines
ZYN has expanded its nicotine pouch portfolio in the Philippines with the addition of Cool Breeze 1.5mg and Tropical in 3mg and 6mg strengths. Public information shows that 1.5mg is among the lower nicotine strengths offered by ZYN in the Philippine market and is positioned for adult nicotine consumers who are new to nicotine pouches.
PMI
Jun.08
Imperial Brands Pulls myblu Vape Business From U.S., Citing Prolonged FDA Approval Process
Imperial Brands Pulls myblu Vape Business From U.S., Citing Prolonged FDA Approval Process
Imperial Brands said it will phase out its myblu vaping business in the United States, citing prolonged FDA approval timelines for new vape products. The company said it will instead focus on modern oral nicotine products in the U.S., including the expansion of its Zone brand and new flavors. While overall next-generation product revenue continued to grow, revenue from the category in the Americas declined sharply.
May.12
Italy Fines PMI €7 Million Over Misleading ‘Smoke-Free Future’ Marketing Claims
Italy Fines PMI €7 Million Over Misleading ‘Smoke-Free Future’ Marketing Claims
Italy’s Competition and Market Authority (AGCM) has fined Philip Morris Italia €7 million, finding that the company’s use of “smoke-free future” and related claims in promoting products such as IQOS, VEEV and ZYN could mislead consumers.
Jun.16
China Tobacco Yunnan Patent Describes Cigar Flavor Granules With Encapsulation Rate Above 77%
China Tobacco Yunnan Patent Describes Cigar Flavor Granules With Encapsulation Rate Above 77%
According to public records from China’s National Intellectual Property Administration, a patent application filed by China Tobacco Yunnan Industrial Co., Ltd. for “cigar flavor granules” was published on May 12, 2026. The filing proposes purifying an ethanol extract of cigar tobacco leaves using LX-8 macroporous resin, followed by encapsulation with maltodextrin and sucrose fatty acid ester to improve smoking comfort, reduce dryness and enhance aroma release stability in reconstituted tobacco.
Jun.10